Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)Research in context

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)Research in context

Background: The POP Trial was a phase 1, open-label, rising-dose, randomised study that explored the safety and tolerability of calmangafodipir (superoxide dismutase mimetic) co-treatment with n-acetylcysteine (NAC) for paracetamol overdose. Methods: Patients were recruited at the Royal Infirmary of...

Full description

Bibliographic Details
Main Authors: Emma E. Morrison, Katherine Oatey, Bernadette Gallagher, Julia Grahamslaw, Rachel O'Brien, Polly Black, Wilna Oosthuyzen, Robert J. Lee, Christopher J. Weir, Dennis Henriksen, James W. Dear
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419304487

Internet

http://www.sciencedirect.com/science/article/pii/S2352396419304487

Similar Items